Nomura H, Aoki D, Susumu N, et al. - Researchers investigated patterns and risk factors of relapse after postoperative adjuvant chemotherapy for endometrial cancer. They studied patients with recurrence among patients enrolled in a randomized phase 3 trial (JGOG2043) examining the effectiveness of adjuvant chemotherapy for endometrial cancer at a high risk of progression. Analysis of 193 patients was done; of these, 50% experienced a local relapse and 63% had a distant relapse. This indicates a similar frequency of local relapse and distant relapse after adjuvant chemotherapy. The median disease-free interval of about 12 months was reported. Disease-free interval (DFI) ≤ 12 months was observed in significant correlation to the following factors: residual tumor at surgery, Grade 3 histology, and lymph node metastasis. In contrast, DFI > 12 months was evident in significant correlation with treatment with paclitaxel and carboplatin. The median postrelapse overall survival (RS) of 23.9 months was reported. In multivariate analysis, poor RS was evident in independent correlation with CA125 ≥ 100 U/mL prior to relapse, distant metastasis, DFI ≤ 12 months, and not performing para-aortic lymphadenectomy.